CYCN - Cyclerion Therapeutics, Inc. Return on Sales by Net Profit

cyclerion.com - graphic logo of issuer CYCN

Cyclerion Therapeutics maintains stability supported by sufficient R&D capital, which is confirmed by the net profitability of sales on the GURU.Markets platform, where the current level is -353.00. The diversification of brain-related drugs mitigates the risks associated with a single test. Additionally, the company is implementing energy saving and emission filtration in its laboratories, strictly adhering to ESG environmental standards.

cyclerion.com (CYCN) - Net Profit Rate from 07/04/2022 to 09/09/2026

cyclerion.com (CYCN) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Initial company analysis:Cyclerion Therapeutics
Manufactured product of Cyclerion Therapeutics

The market assesses Cyclerion Therapeutics (CYCN) as a high-risk asset in an intensive R&D stage. Net profitability measures the portion of profit in every dollar of revenue after deducting all operating and financial expenses. By analyzing the sales margin, an investor can see the capital burn rate in the absence of commercial revenues. For a biotech company, this indicator reflects a critical dependence on liquidity. Negative dynamics confirm a phase of depleting reserves.

Competing companies

BIIB: Net Sales Margin|Net Margin Neurocrine Biosciences Inc (NBIX)|RGC (Regencell Corp) - Net Sales Margin|AXSM: Net Profit Rate|Net Margin acadia-pharm.com (ACAD)|Net Sales Margin Xenon Pharmaceuticals (XENE)|Net Margin Viking Therapeutics VKTX|Net Profit Rate SUPN|CPRX - Net Margin|Net Margin Denali Therapeutics|HRMY: Net Sales Margin|Biohaven - Net Profit Rate|Return on Sales by Net Profit AMLX|Trevi Therapeutics, Inc. (TRVI) - Company Sales Margin|Return on Sales by Net Profit PRAX (Praxis Medicines)|Anavex Corp - Net Return on Sales|Net Margin CeriBell CBLL|Company Sales Margin Prothena Biosciences (PRTA)|ALEC: Return on Sales by Net Profit|ANNX - Net Sales Margin|Omeros Corp. (OMER) - Net Margin|Net Margin Neurogene Inc. (NGNE)|Return on Sales by Net Profit ACIU|Net Margin VYGR|Net Margin Neumora (NMRA)|SCLX - Net Margin|Net Sales Margin TVGN (Tevogen Bio Holdings Inc.)|Net Profit Rate ACOG|Cognition Therapeutics Inc. - Net Sales Margin|IKT - Net Sales Margin|SAVA: Net Sales Margin|Assertio Holdings, Inc. - Net Profit Rate|COYA (Coya) - Net Sales Margin|Net Return on Sales VTGN (Vistagen Therapeutics)|Net Margin Ovid Rx (OVID)|Acumen Pharmaceuticals - Net Return on Sales|Net Margin CervoMed, Inc. CRVO|Net Sales Margin Alterity Therapeutics ATHE|CLNN: Return on Sales by Net Profit|PEPG (pepgen.com) - Net Return on Sales|Jupiter Neurosciences Inc (JUNS) - Net Margin|Relmada Therapeutics - Net Profit Rate|ANVS (Annovis Bio Inc) - Net Sales Margin|GRCE: Net Profit Rate|Net Margin Firefly Neuroscience Inc (AIFF)|KLTO (ANEW Medical) - Net Profit Rate|Net Margin neurosense-tx.com NRSN|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Net Margin|MTVA: Return on Sales by Net Profit|NeurAxis, Inc (NRXS) - Return on Sales by Net Profit|HSDT: Net Sales Margin|PASG - Company Sales Margin|Net Margin Neuphoria Therapeutics, Inc.|Net Margin NERV|Net Sales Margin ATHA|ADXN (Addex Therapeutics Ltd) - Net Profit Rate|Net Margin alzamend.com ALZN|Net Profitability Margin Protagenic|KTTA: Return on Sales by Net Profit|Net Profit Rate CRGT (cortigent.com)|ATXI: Net Sales Margin|BCLI (BrainStorm Cell Therapeutics) - Net Margin|CARA (Cara Therapeutics Inc.) - Net Sales Margin|Net Margin CHRO|Return on Sales by Net Profit ELYM (Eliem Therapeutics)|Net Margin ITCI (Intra-Cellular Therapies Inc.)|Net Sales Margin LBPH (Longboard Pharma)|Net Sales Margin Marinus Pharmaceuticals Inc MRNS|NKGen Biotech Corp - Net Sales Margin|Net Profit Rate NRBO (NeuroBo Pharma)|SAGE (Sage Therapeutics, Inc) - Return on Sales by Net Profit|Net Return on Sales SNPX|Return on Sales by Net Profit TRVN|Net Margin VIGL|Net Sales Margin WENA|Company Sales Margin Cerevel